GENE ONLINE|News &
Opinion
Blog

Rare Disease
GeneOnline’s Pick: Top 10 M&A Deals in 2022
2022-12-28
AstraZeneca’s Treatment for Rare Throat Disease, Eosinophilic esophagitis, Fails Primary Endpoint
2022-10-25
Bristol Myers Squibb’ sNDA for Rare Heart Disease Treatment Accepted by the FDA
2022-10-21
Nineteen Grants and Two Contracts Grab $38 Million In Support From the FDA
2022-10-17
Albireo Signals To Apply For FDA Approval After Trial Win
2022-10-12
AstraZeneca’s Rare Disease Treatment Wins Third Approval in European Union
2022-09-23
BridgeBio and Sentynl Therapeutics’ Nulibry Gets Greenlighted In Europe
2022-09-21
QOL Medical’s Sucraid Single-Use Containers Approved For Patients With Sucrase Deficiency
2022-09-07
BioCryst’s ALK-2 Inhibitor Granted FDA Orphan Drug Status For Rare Bone Disease
2022-09-01
Sanofi’s Rare Disease Drug Granted First-Ever FDA Approval for the Condition
2022-09-01
Everest, Calliditas Win First Approval for Rare Kidney Disease Drug in Europe
2022-07-18
How Governments Around the World Should Respond to the Mounting Costs of Gene and Cell Therapy?
2022-07-08
Quion Licenses Two Rare Skin Disease Candidates to Hong Kong WinHealth
2022-06-16
FDA Lifts Hold on LogicBio’s Gene Editing Program
2022-05-10
Shanghai’s Hasten Seals $322 Million Acquisition of Takeda Drugs
2022-04-06
1 2 3 4
LATEST
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
2023-02-07
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
2023-02-06
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
First Human Trial for Marburg Virus Vaccine Reports Success
2023-02-03
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!